Actively Recruiting
Randomized Double-Blind Trial Comparing Vigabatrin and Rapamycin for Preventing Symptoms in Infants With Tuberous Sclerosis Complex
Led by Katarzyna Kotulska · Updated on 2026-10-22
60
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, tolerability, and safety of two preventive treatments, vigabatrin and rapamycin, in infants diagnosed with Tuberous Sclerosis Complex TSC. This randomized, double-blind, double-dummy, placebo-controlled study aims to compare these treatments in preventing symptoms associated with TSC, including clinical seizures and tumor growth. The trial plans to enroll approximately 60 infants aged between 4 and 16 weeks at randomization. Participants will be randomly assigned in equal groups to receive either vigabatrin capsules with liquid placebo or rapamycin liquid with placebo capsules. Vigabatrin is given orally once daily at first, then twice daily starting from the second visit. Rapamycin is administered orally in liquid form every other day or daily based on body weight, with dose calculated at the first visit. The study includes three phases for each infant screening, a core blinded phase lasting up to 730 days, and an open-label follow-up phase. During participation, infants will undergo evaluations including brain MRI to assess tumor volume, video electroencephalography videoEEG to monitor epileptiform activity, and psychological tests to evaluate autism risk and developmental progress. Researchers will track the occurrence of clinical seizures, tumor growth, adverse events, and physical development such as weight and height over two years. Safety and tolerability will be closely monitored throughout the blinded and open-label phases, with continued follow-up to assess long-term outcomes.
CONDITIONS
Brief Title
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Research Team
K
Katarzyna Kotulska-Jozwiak
M
Monika Szkop
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here